These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Hepatic microvascular regulatory mechanisms. IV. Effect of lodoxamide tromethamine and arterenol-HCl on vascular responses evoked by compound 48/80.
    Author: Reilly FD, Dimlich RV.
    Journal: Microcirc Endothelium Lymphatics; 1984 Feb; 1(1):87-106. PubMed ID: 6152810.
    Abstract:
    Changes in the hepatic microvasculature and systemic arterial blood pressure were measured in anesthetized Sprague-Dawley rats receiving an i.v. infusion or topical application of compound 48/80, lodoxamide, or arterenol. Histochemical determination of the number of Falck-Hillarp positive (serotonin containing) mast cells also was performed on sections of liver at the light microscopic level. The infusion of arterenol (0.1 mg/kg) or Ringer's solution (control) provoked a vasopressor response within 25 sec in rats rendered hypotensive 5 min previously with compound 48/80. The duration of this response was brief with arterial pressure returning to the pre-injection (hypotensive) state within 3 min following arterenol or Ringer's administration. The injection of lodoxamide (a purported inhibitor of histamine release) inhibited compound 48/80-induced hypotension at all doses except 1 mg/kg. In vivo microscopy revealed that topical administration (0.1 microgram) significantly antagonized the microvascular responses elicited by compound 48/80. However, higher doses of lodoxamide (1.0-10 micrograms) when applied topically were found to be vasoactive. Given these results and the histochemical demonstration of an inhibition of compound 48/80-induced release of serotonin, it is suggested that: lodoxamide antagonizes the action of compound 48/80 by blocking the release of mast cell constituents, and neither compound 48/80 nor the released constituents appear to modify vascular responsiveness to arterenol or hypervolemia following the initiation of hypotension.
    [Abstract] [Full Text] [Related] [New Search]